Rituxan® (Rituximab), our first product approved for marketing in the United States, and our primary products still under development, address immune system disorders, such as lymphomas and autoimmune and inflammatory diseases, such as psoriasis, rheumatoid arthritis and allergic asthma. The products are either commercialized or in preclinical and clinical development by IDEC and its partners.